Potřebujeme váš souhlas k využití jednotlivých dat, aby se vám mimo jiné mohly ukazovat informace týkající se vašich zájmů. Souhlas udělíte kliknutím na tlačítko „OK“.
Standard Guide for Multivariate Data Analysis in Pharmaceutical Development and Manufacturing Applications
Automaticky přeložený název:
Standardní Guide vícerozměrné analýza dat ve farmaceutickém vývoji a výrobě aplikace
NORMA vydána dne 1.11.2013
Označení normy: ASTM E2891-13
Poznámka: NEPLATNÁ
Datum vydání normy: 1.11.2013
Kód zboží: NS-46208
Počet stran: 6
Přibližná hmotnost: 18 g (0.04 liber)
Země: Americká technická norma
Kategorie: Technické normy ASTM
Farmacie obecně
Aplikace informační technologie ve zdravotnictví
Keywords:
chemometrics, chemometric model, data analysis method validation, data model, exploratory data analysis, model building, model validation, multivariate data analysis, outliers, predictive data analysis, process analytical technology, ICS Number Code 11.120.01 (Pharmaceutics in general), 35.240.80 (IT applications in health care technology)
Significance and Use | ||||||||||||||||||||||
4.1 A significant amount of data is being generated during pharmaceutical development and manufacturing activities. The interpretation of such data is becoming increasingly difficult. Individual examination of the univariate process variables is relevant but can be significantly complemented by multivariate data analysis (MVDA). Such methodology has been shown to be particularly efficient at handling large amounts of data from multiple sources, summarizing complex information into meaningful low dimensional graphical representations, identifying intricate correlations between multivariate datasets taking into account variable interactions. The output from MVDA will generate useful information that can be used to enhance process understanding, decision making in process development, process monitoring and control (including product release), product life-cycle management and continual improvement. 4.2 MVDA is a widely used tool in various industries including the pharmaceutical industry. To generate a valid outcome, MVDA should contain the following components: 4.2.1 A predefined objective based on a risk and scientific hypothesis specific to the application, 4.2.2 Relevant data, 4.2.3 Appropriate data analysis techniques, including considerations on validation, 4.2.4 Appropriately trained staff, and 4.2.5 Life-cycle management. 4.3 This guide can be used to support data analysis activities associated with pharmaceutical development and manufacturing, process performance and product quality monitoring in manufacturing, as well as for troubleshooting and investigation events. Technical details in data analysis can be found in scientific literature and standard practices in data analysis are already available (such as Practices E1655 and E1790 for spectroscopic applications, Practice E2617 for model validation and Practice E2474 for utilizing process analytical technology). |
||||||||||||||||||||||
1. Scope | ||||||||||||||||||||||
1.1 This guide covers the applications of multivariate data analysis (MVDA) to support pharmaceutical development and manufacturing activities. MVDA is one of the key enablers for process understanding and decision making in pharmaceutical development, and for the release of intermediate and final products. 1.2 The scope of this guide is to provide general guidelines on the application of MVDA in the pharmaceutical industry. While MVDA refers to typical empirical data analysis, the scope is limited to providing a high level guidance and not intended to provide application-specific data analysis procedures. This guide provides considerations on the following aspects: 1.2.1 Use of a risk-based approach (understanding the objective requirements and assessing the fit-for-use status), 1.2.2 Considerations on the data collection and diagnostics used for MVDA (including data preprocessing and outliers), 1.2.3 Considerations on the different types of data analysis and model validation, 1.2.4 Qualified and competent personnel, and 1.2.5 Life-cycle management of MVDA. 1.3 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use. |
||||||||||||||||||||||
2. Referenced Documents | ||||||||||||||||||||||
|
Historická
1.4.2014
Historická
15.4.2010
Historická
1.1.2008
Historická
1.3.2014
Historická
1.8.2009
Historická
1.8.2009
Poslední aktualizace: 04.11.2024 (Počet položek: 2 209 323)
© Copyright 2024 NORMSERVIS s.r.o.